Introduction
============

Although the exercise tolerance test (ETT) has been widely used in clinical practice, the value of blood pressure (BP) response to ETT remains unclear,^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ especially regarding the relationship between BP response during exercise and future cardiovascular events. The current guidelines include exercise-induced hypertension as a marker for future hypertension but not for cardiovascular morbidity and mortality outcomes.^[@bib11],\ [@bib12]^ Several recent studies have shown that BP response at submaximal rather than at maximal workload was associated with future cardiovascular disease (CVD) in normotensive patients,^[@bib6],\ [@bib8],\ [@bib10]^ but the prognostic value of BP response during ETT in hypertensive patients has not yet been determined. At our center, a diagnosis of hypertension is based on 24-h ambulatory blood pressure monitoring (ABPM), with ETT using the Naughton/Balke protocol utilized for cardiac rehabilitation and risk stratification. Because almost all the patients in our registry, the Asan-ABPM registry, underwent ETT at initial evaluation, we assessed the prognostic value of submaximal systolic BP (SBP) response during exercise for future cardiovascular events in patients with mild-to-moderate sustained hypertension (sHT) diagnosed by 24-h ABPM.

Methods
=======

We enrolled patients aged ⩾18 years who were registered in the Asan-ABPM registry between May 2002 and October 2005. Patients were excluded if they had a history of coronary artery disease or stroke at the time of hospital visit, symptomatic congestive heart failure or failed to achieve the target heart rate. Of the 1017 patients screened, 886 (87.1%) were taking antihypertensive medications at the time of ETT, whereas 131 (12.9%) were not. We identified 541 patients diagnosed with sHT by ABPM. We excluded 190 patients who had not achieved target heart rate, 42 with previous ischemic heart disease (IHD) or stroke and 9 with stage 3 hypertension. Therefore, our study population consisted of 300 patients with sHT ([Figure 1](#fig1){ref-type="fig"}). The study protocol was approved by the Ethical Committee of our institution.

All the patients receiving antihypertensive medications were asked to discontinue them for at least five half-lives of the drug. Clinical BPs were measured by the physician investigators using a mercury sphygmomanometer, with SBP and diastolic BP (DBP) at rest measured in the left brachial artery after at least 5--10 min of rest, with two readings taken 5 min apart. Ambulatory BP was measured using 24-h ABPM with a portable SpaceLabs 90207 (Issaquah, WA, USA) noninvasive recorder with a BP cuff fitted on the nondominant arm. The unit was programmed to record BP and heart rate at 15-min intervals from 0600 to 2200 hours (daytime period) and at 30-min intervals from 2200 to 0600 hours (night period); awake and asleep periods were calculated from diary entries. sHT was defined as a daytime BP ⩾135/85 mm Hg and a night BP ⩾120/70 mm Hg.^[@bib12]^

We also assessed the clinical and family history of each patient, as well as the results of physical examination, laboratory parameters, echocardiography and exercise treadmill tests. We also calculated the Framingham general cardiovascular risk score for each patient.^[@bib13]^

ETTs were performed using a symptom-limited Naughton/Balke treadmill protocol. Attainment of 85% of target heart rates (age- and sex-predicted maximal heart rate) was considered adequate. Target heart rates were not considered predetermined end points, rather subjects underwent symptom-limited treadmill tests. Throughout the ETT, BP and heart rate were measured using a SunTech Medical Tango BP monitoring system (Raleigh, NC, USA), with baseline measurements taken with the subject at rest in a sitting position prior to exercise. Heart rate (HR) was monitored continuously using a 12-lead echocardiogram. SBP and DBP were measured by auscultation for 30 s before the end of each 2-min incremental stage. Multi-lead ECG recordings were taken at rest and at the same interval until the end of the recovery period to exclude ischemia or arrhythmia. Exercise capacity was calculated as the total metabolic equivalent tasks achieved. All the patients were categorized into quartiles based on their absolute value of SBP response at stage 4 of the Naughton/Balke treadmill protocol (7.4 metabolic equivalent tasks). We also assessed DBP at stage 4 and SBP and DBP at the maximal workload for each individual. If a patient was unable to reach stage 4, the highest SBP through stage 3 was used.

The primary outcome of this study was the composite of all-cause death, new-onset IHD and stroke. The cause and date of death were confirmed by information gathered from the national population registry of the Korean national statistical office, together with a review of all the available clinical records. Follow-up data were also collected by direct telephone interview and a review of medical records. IHD was diagnosed in patients with typical angina symptoms and positive results on at least one stress test (ETT, thallium scan or dobutamine stress echocardiography). Stroke was diagnosed by an independent neurologist based on brain imaging. The patients were followed for a median of 66 months (interquartile range 34--79 months).

All the statistical analyses were performed using SPSS (version 18.0; SPSS Inc, Chicago, IL, USA). Summary statistics are presented as frequencies and percentages, mean±s.d. or medians with interquartile ranges. Between-group differences in continuous variables were assessed by analysis of variance and turkey\'s tests, whereas between-group differences in the frequency of categorical variables were assessed using the Chi-square or Fisher\'s exact tests, as appropriate. Relationship between BP variables measured during ETT was evaluated by calculation of Spearman\'s rank correlation coefficient. Cumulative survival and event-free rate curves were calculated by the Kaplan--Meier method and compared using the log-rank test. We used three-step adjustment using Cox proportional hazard models to adjust for confounding variables. In model 1, unadjusted HR was adjusted for resting SBP and DBP during ETT. In model 2, HR was further adjusted for Framingham general cardiovascular risk score and other confounding variables were adjusted in model 3. All *P*-values were two-sided, and *P*\<0.05 was considered statistically significant.

Results
=======

The study participants were middle aged (mean 50.4±11.17 years old) with more men (56.7%) included ([Table 1](#tbl1){ref-type="table"}). The 300 participants showing SBP increases during exercise were divided into quartiles based on their BP responses at stage 4 of the ETT. The clinical and exercise characteristics of the study population are shown in [Table 2](#tbl2){ref-type="table"}. Compared with participants who had the lowest quartile of SBP increases, those with increases in the highest quartile were older, had higher body mass index and Framingham scores, as well as had higher clinical SBP, DBP and night SBP. During ETT, patients in quartile 4 showed the earliest target-HR achievement and lowest exercise capacity. There was no significant difference in alcohol consumption, smoking history and lipid profile across the quartiles. Distributions of BP responses during exercise are shown in [Table 3](#tbl3){ref-type="table"}. Participants in the highest quartile showed a greater increase in SBP and a lesser decrease in DBP at submaximal and maximal exercise BP. In the correlation matrix ([Table 4](#tbl4){ref-type="table"}), the absolute value of stage 4 SBP showed strong positive correlation with the change of SBP at stage 4 (*r*=0.791, *P*=0.001) and the absolute SBP value at maximal workload (*r*=0.680, *P*=0.001), whereas relationship with the DBP variables were weaker.

Unadjusted survival analysis using the Kaplan--Meier method showed that the 5-year overall survival rate did not differ significantly among quartiles 1--4 (100% *vs*. 96.6% *vs*. 94.4% *vs*. 98.3%, *P*=0.211). However, there was a trend of lower 5-year event-free survival rate in a higher quartile (98.3% *vs*. 95.0% *vs*. 88.2% *vs*. 86.9%, *P*=0.064). Compared with patients in quartile 1, the 5-year event-free survival rate was significantly lower for patients in quartiles 3 (86.9% *vs*. 98.3%, *P*=0.022) and 4 (88.2% *vs*. 98.3%, *P*=0.023). The details of composite outcomes are described in [Table 5](#tbl5){ref-type="table"}. During 5 years, more cardiovascular events occurred in a higher quartile (1.3% *vs*. 3.9% *vs*. 10.3% *vs*. 9.9%, *P*=0.028) and the difference in event-free survival was mainly driven by new-onset IHD.

Results of multivariable models relating exercise BP to the composite risk of death, IHD and stroke are shown in [Table 6](#tbl6){ref-type="table"}. After adjusting for resting SBP and DBP, we found that, compared with patients in quartiles 1 and 2, those in quartiles 3 (HR 4.52, 95% confidence interval (CI) 1.33--15.29, *P*=0.015) and 4 (HR 5.16, 95% CI 1.42--18.88, *P*=0.013) were at significantly higher risk of composite outcomes (see [Table 6](#tbl6){ref-type="table"}). These differences remained significant after adjusting for Framingham risk scores. In Model 3, even after adjustment for known risk factors, exercise capacity and ABPM data, patients in quartiles 3 and 4 tended to have higher risks of composite outcomes than those in quartile 1, however, the difference was not significant for those in quartile 4. However, when assessing quartiles as a continuous variable, multivariate analysis models showed that each 8-min SBP increment was associated with an increase in HR of 1.76 (95% CI 1.12--2.78, *P*=0.010), which remained significant after adjusting for resting SBP, DBP, Framingham score and all the other variables. (HR 1.74, 95% CI 1.04--2.89, *P*=0.035). Further analysis comparing 8-min SBP \>180 (upper 50% of total population) and ⩽180 mm Hg (lower 50% of total population) showed that the former group was at significantly increased risk of composite end points (HR 3.74, 95% CI 1.24--11.28, *P*=0.019), even after adjustment for all the other variables (HR 4.00, 95% CI 1.19--13.44, *P*=0.025).

Discussion
==========

The most important finding of this study of patients with uncomplicated mild-to-moderate sHT was that those in higher quartiles were associated with higher risk of the composite end point in unadjusted analysis. During ETT, patients in higher quartiles showed greater incremental increases in SBP and lower decrements in DBP. Clinically, patients in higher quartiles had higher daytime and night SBP during ABPM, as well as more risk factors for CVD, including higher Framingham score and body mass index and lower exercise capacity. Moreover, patients in higher quartiles were at high risk of the composite end point, even after adjustment for known CVD risk factors.

Although most prior studies focused on peak SBP at maximal workload,^[@bib1],\ [@bib3],\ [@bib4],\ [@bib7],\ [@bib9],\ [@bib10]^ we considered SBP at submaximal workload in the Naughton/Balke protocol as more valuable for several reasons. First, because submaximal workload was easily achieved by patients with lower exercise capacity, we could include representative data from more patients. Second, because the Naughton/Balke protocol used smaller increments in workload, this protocol could more accurately portray functional capacity than the Bruce protocol, as well as minimizing contamination by mental factors. Third, we regarded data from a treadmill test as more valuable than data from a bicycle ergometer because maximal oxygen uptake is generally lower on the latter.^[@bib14]^ Moreover, because the legs of individuals from east Asia are usually shorter than those of Caucasians, a bicycle ergometer may underestimate the exact workload of exercise. In addition, all of our patients underwent ABPM monitoring at the beginning of treatment, thus, confirming sHT and allowing ABPM data to be integrated into multivariate analysis models. As a result, our study included a homogeneous group of patients with mild-to-moderate sHT relevant to clinical practice, allowing the independent prognostic value of ETT results to be determined.

Large population studies have shown an association between SBP response during submaximal ETT and CVD. For example, the relationship between submaximal SBP and cardiovascular mortality was assessed in normotensive patients using a bicycle ergometer.^[@bib10]^ That study showed that 6-min SBP, representing 55% of the mean exercise capacity of the entire population, was associated with cardiovascular mortality after multivariate adjustment, a finding consistent with our results despite our inclusion of only hypertensive patients. In addition, a study of \>6000 patients found an association between Bruce stage 2 SBP ⩾180 mm Hg and future CVD in non-hypertensive patients.^[@bib8]^ In extending these findings to hypertensive patients, we found that a greater increase in BP was associated with higher morbidity and mortality rates and was a clinical risk factor for CVD.

The mechanism underlying the association between exercise SBP response and CVD has not yet been determined. In healthy patients, an increase in cardiac output is usually accompanied by an increase in SBP, but may be attenuated by adaptive vasodilatation of peripheral vessels.^[@bib15]^ An exaggerated SBP response during ETT has been regarded as a consequence of mismatching between these two mechanisms. Interestingly, outcomes in our patients were exactly the opposite of that in patients with known IHD, in that exaggerated exercise SBP had protective effects on outcomes, which may be associated with better cardiac output augmentation.^[@bib2],\ [@bib16]^ Because we excluded patients with impaired cardiac output augmentation, impaired adaptive vasodilatation may be a more important mechanism in our study. Several studies have shown a relationship between impaired vasodilatation and greater BP response.^[@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^ This mechanism may be reflected in the characteristics of the BP response in the patients in higher quartiles of the present study, including greater SBP increment and reduced DBP decrement, despite lower exercise capacity, higher daytime and night SBP during ABPM monitoring. A continuous exposure to high BP during daily activity may lead to a high CVD rate for patients in the upper quartiles.^[@bib21],\ [@bib22],\ [@bib23]^

In addition to their differing SBP response, the differences in baseline characteristics among patients in different quartiles may have affected the clinical outcomes. Patients in higher quartiles were older, had higher body mass index and clinical and ABPM BP, and lower exercise capacity than those in lower quartiles. In particular, the Framingham general CVD score, a strong prognostic factor, was significantly higher for patients in quartile 4.^[@bib13]^ The submaximal ETT response among our patients was well correlated with their general CVD risk factors, resulting in differences in primary outcomes on unadjusted survival analysis. Thus, in addition to being an independent prognostic factor, higher SBP response during ETT may itself be a marker of future CVD risk.

The primary limitations of our study were the relatively small patient cohort and short follow-up period, resulting in a relatively low incidence of clinical events. The limitation in cohort size was mainly due to the exclusion of patients with pre-existing CVD and those at high risk of CVD. A follow-up period of 5 years may be too short to show the clinical significance in patients at mild-to-moderate risk. To overcome the limited numbers of patients and observed events, we had to use the Framingham risk score as a surrogate marker of many cardiovascular risk factors such as age, sex, smoking status and lipid profiles. As a result, age and sex itself were not included in our three-step models because of the limited number of observed events and multicollinearity. And we had to summate the quartiles 1 and 2 as a reference to calculate the HR of quartiles 3 and 4. However, our exclusion criteria enabled our assessment of new CVD in a homogeneous patient group, and these patients could be intensively followed-up because the study was performed in a single center. Because some of our patients may have become fatigued before reaching their maximal exercise capacities, we may have underestimated maximal BP. However, the submaximal SBP we observed was likely correct because almost all of the patients exercised for more than stage 4.

Conclusion
==========

In conclusion, the submaximal SBP response at stage 4 (8 min) of the Naughton/Balke protocol may be a good predictor of future cardiovascular events in patients with mild-to-moderate sHT. And patients with stage 4 SBP \>180 mm Hg were at significantly higher cardiovascular risk, even after adjustment for other risk factors, than those with lower SBP.
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###### Baseline characteristics

                                    *Overall*    *Men*         *Women*
  --------------------------------- ------------ ------------- ------------
  Age, years                        50.4±11.17   47.2±10.9     54.5±10.1
  BMI kg m^−2^                      25.5±3.1     25.9±2.9      25.1±3.3
  Alcohol (%)                       147 (49)     127 (74.7)    20 (15.4)
  Smoking (%)                       113 (37.7)   111 (65.3)    2 (1.5)
  DM (%)                            7 (2.3)      3 (1.8)       4 (3.1)
  Total cholesterol, mg dl^−1^      195.7±37.6   193.6±36.7    198.4±38.7
   TG, mg dl^−1^                    152.3±98.3   166.1±105.5   134.0±85.0
   HDL, mg dl^−1^                   53.6±16.8    50.1±12.4     58.2±20.4
                                                                
  *BP medication (%)*               270 (90)     154 (90.6)    116 (89.2)
   Clinical BP                                                 
    SBP, mm Hg                      161.4±18.9   159.4±17.6    163.9±20.5
    DBP, mm Hg                      99.6±11.7    101.8±96.7    96.7±11.8
   Wake BP                                                     
    SBP, mm Hg                      142.2±10.9   142.3±11.5    142.1±10.1
    DBP, mm Hg                      91.0±8.1     92.1±7.9      89.6±8.0
   Sleep BP                                                    
    SBP, mm Hg                      129.7±14.4   128.1±14.5    131.9±14.1
    DBP, mm Hg                      81.8±9.6     81.9±9.8      81.5±9.3
  Exercise capacity (METs)          9.4±1.5      9.8±1.3       8.8±1.7
  Exercise time (min)               12.4±3.2     13.1±2.9      11.5±3.3
  Time to achieve target HR (min)   9.9±4.3      11.0±3.7      8.4±4.4
  LV wall mass index, mg m^−2^      97.7±18.6    101.1±17.1    93.5±19.6
  Framingham score                  11.1±4.3     11.5±4.3      10.5±4.2

Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL, high-density lipoprotein; HR, heart rate; LV, left ventricle; METs, metabolic equivalent tasks; SBP, systolic blood pressure; TG, triglyceride.

###### Characteristics of the 300 study participants based on SBP changes during 8 min of exercise

                                     *Quartile 1*   *Quartile 2*   *Quartile 3*   *Quartile 4*    
  --------------------------------- -------------- -------------- -------------- --------------- ---------
  Stage 4 SBP range (mm Hg)              ⩽163         164--180       181--196         \>197       
  Age, years                          49.85±10.5     47.4±10.1      52.7±11.2     52.1±12.3^†^   0.021
  Male (%)                            46 (59.0)      42 (55.3)      47 (62.7)       35 (49.3)    0.407
  BMI kg m^−2^                         24.6±2.4       25.3±2.6     26.0±3.5^‡^     26.3±3.6^‡^   0.029
  Alcohol (%)                          39 (50)       35 (46.1)      40 (53.3)       39 (54.9)    0.710
  Smoking (%)                         28 (35.9)      32 (42.1)      26 (34.7)        27 (38)     0.793
  DM (%)                               1 (1.3)        2 (2.6)        1 (1.3)         3 (4.2)     0.604
  Total cholesterol, mg dl^−1^        203.6±40.4     188.1±33.3     197.3±33.1     193.8±42.0    0.077
  TG, mg dl^−1^                       150.3±93.9     151.8±95.3    149.9±108.2     157.3±97.9    0.969
  HDL, mg dl^−1^                      55.8±19.3      53.6±19.3      54.5±15.3       50.3±11.2    0.251
                                                                                                  
  *BP medication* (%)                 69 (88.5)      68 (89.5)      69 (92.0)       64 (90.1)    0.905
   Clinical BP                                                                                   
    SBP, mm Hg                        155.4±17.1     157.8±15.6     164.1±19.7    168.7±20.6^‡^  \<0.001
    DBP, mm Hg                        98.6±10.6      100.8±11.0     100.2±10.9      98.7±14.2    0.630
   Wake BP                                                                                       
    SBP, mm Hg                        136.8±8.9      140.9±10.1     144.2±9.9     147.6±11.8\*   \<0.001
    DBP, mm Hg                         89.8±7.0       92.9±7.9       90.5±7.2       90.9±9.7     0.105
   Sleep BP                                                                                      
    SBP, mm Hg                        123.9±12.9     127.9±14.6     128.2±13.1    137.3±15.1\*   \<0.001
    DBP, mm Hg                         80.5±8.9      83.1±11.0       80.5±8.1       83.5±10.7    0.153
  Exercise capacity (METs)             9.9±1.1        9.7±1.2        9.1±1.7       8.4±1.6\*\*   \<0.001
  Exercise time (min)                  13.8±2.6       13.0±2.8       12.0±3.3      10.5±3.1^‡^   \<0.001
  Time to achieve target HR (min)      11.8±3.2       10.9±4.1      9.4±4.1^‡^     7.3±4.2\*\*   \<0.001
  LV wall mass index, mg m^−2^        94.6±20.2      97.9±16.8      98.2±16.8      100.8±20.3    0.292
  Framingham score                     9.9±4.7        10.2±3.8       11.9±3.7       12.3±4.3     \<0.001

Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL, high-density lipoprotein; HR, heart rate; LV, left ventricle; METs, metabolic equivalent tasks; SBP, systolic blood pressure; TG, triglyceride.

^‡^*P*\<0.05 *vs*. quartile 1.

^†^*P*\<0.05 *vs*. quartile 2.

\**P*\<0.05 *vs.* quartile 1, 2.

\*\**P*\<0.05 *vs*. quartiles 1, 2, 3.

###### Blood pressure responses during exercise

  *Variable*                  *Quartile 1*   *Quartile 2*   *Quartile 3*    *Quartile 4*     P-*value*
  --------------------------- -------------- -------------- --------------- --------------- -----------
  Resting SBP, mm Hg          134.5±12.9     143.0±12.8     144.9±13.0^‡^   151.4±15.4^†^     \<0.001
  SBP at stage 4, mm Hg       149.3±11.8     173.1±5.1      188.5±4.4^‡^    211.5±11.3^†^    \<0.001\*
  ΔSBP at stage 4, mm Hg      14.9±15.3      30.1±12.7      43.6±13.5       60.1±17.7        \<0.001\*
  SBP at maximal WL, mm Hg    166.6±21.6     187.2±20.5     193.8±13.1^‡^   207.4±18.9^†^     \<0.001
  ΔSBP at maximal WL, mm Hg   37.0±20.1      47.8±20.1      54.1±16.4^‡^    62.6±16.9^†^      \<0.001
  Resting DBP, mm Hg          91.3±9.9       97.3±11.7      95.9±11.2       97.75±12.5^‡^     \<0.001
  DBP at stage 4, mm Hg       80.7±12.4      89.5±11.7^‡^   90.4±13.4^‡^    95.3±12.1^‡^      \<0.001
  ΔDBP at stage 4, mm Hg      −10.6±11.7     −7.7±13.7^‡^   −5.4±14.6^‡^    −2.4±12.5^‡^      \<0.001
  DBP at maximal WL, mm Hg    80.9±13.0      90.5±13.6^‡^   89.8±13.6^‡^    93.9±13.3^‡^      \<0.001
  ΔDBP at maximal WL, mm Hg   −10.3±14.0     −6.7±14.4      −6.1±15.2       −3.7±12.7^‡^       0.040

Abbreviations: DBP, diastolic blood pressure; ΔDBP, DBP change from baseline; SBP, systolic blood pressure; ΔSBP, SBP change from baseline; WL, work load.

^†^*P*\<0.05 *vs*. quartile 1, 2 and 3.

^‡^*P*\<0.05 *vs.* quartile 1.

\**P*\<0.05 in every quartile.

###### The correlation matrix of measured BP variables during ETT

                                          *1*                 *2*                                *3*                                *4*                                *5*                                *6*                                 *7*                                *8*                                *9*                                *10*
  ----------------------- ----------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ----------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ------
  1 Resting SBP                           ---                                                                                                                                                                                                                                                                                                           
  2 SBP at stage 4         0.398[a](#t4-fn1){ref-type="fn"}   ---                                                                                                                                                                                                                                                                                       
  3 ΔSBP at stage 4        −0.196[a](#t4-fn1){ref-type="fn"}  0.791[a](#t4-fn1){ref-type="fn"}   ---                                                                                                                                                                                                                                                    
  4 SBP at maximal WL      0.376[a](#t4-fn1){ref-type="fn"}   0.680[a](#t4-fn1){ref-type="fn"}   0.491[a](#t4-fn1){ref-type="fn"}   ---                                                                                                                                                                                                                 
  5 ΔSBP at maximal WL     −0.258[a](#t4-fn1){ref-type="fn"}  0.417[a](#t4-fn1){ref-type="fn"}   0.643[a](#t4-fn1){ref-type="fn"}   0.767[a](#t4-fn1){ref-type="fn"}   ---                                                                                                                                                                              
  6 Resting DBP            0.389[a](#t4-fn1){ref-type="fn"}   0.200[a](#t4-fn1){ref-type="fn"}   −0.44                              0.147[b](#t4-fn2){ref-type="fn"}   −0.105                             ---                                                                                                                                           
  7 DBP at stage 4         0.248[a](#t4-fn1){ref-type="fn"}   0.406[a](#t4-fn1){ref-type="fn"}   0.260[a](#t4-fn1){ref-type="fn"}   0.301[a](#t4-fn1){ref-type="fn"}   0.143[b](#t4-fn2){ref-type="fn"}   0.396[a](#t4-fn1){ref-type="fn"}    ---                                                                                                       
  8 ΔDBP at stage 4                     −0.102                0.219[a](#t4-fn1){ref-type="fn"}   0.306[a](#t4-fn1){ref-type="fn"}   0.146[b](#t4-fn2){ref-type="fn"}   0.225[a](#t4-fn1){ref-type="fn"}   −0.422[a](#t4-fn1){ref-type="fn"}   0.612[a](#t4-fn1){ref-type="fn"}   ---                                                                    
  9 DBP at maximal WL      0.241[a](#t4-fn1){ref-type="fn"}   0.324[a](#t4-fn1){ref-type="fn"}   0.189[a](#t4-fn1){ref-type="fn"}   0.315[a](#t4-fn1){ref-type="fn"}   0.178[a](#t4-fn1){ref-type="fn"}   0.383[a](#t4-fn1){ref-type="fn"}    0.771[a](#t4-fn1){ref-type="fn"}   0.421[a](#t4-fn1){ref-type="fn"}   ---                                 
  10 ΔDBP at maximal WL                 −0.091                0.128[b](#t4-fn2){ref-type="fn"}   0.212[a](#t4-fn1){ref-type="fn"}   0.176[a](#t4-fn1){ref-type="fn"}   0.263[a](#t4-fn1){ref-type="fn"}   −0.395[a](#t4-fn1){ref-type="fn"}   0.419[a](#t4-fn1){ref-type="fn"}   0.778[a](#t4-fn1){ref-type="fn"}   0.650[a](#t4-fn1){ref-type="fn"}   ---

Abbreviations: DBP, diastolic blood pressure; ΔDBP, DBP change from baseline; SBP, systolic blood pressure; ΔSBP, SBP change from baseline; WL, work load.

Correlation is significant at the 0.01 level (two-tailed).

Correlation is significant at the 0.05 level (two-tailed).

###### Comparison of clinical outcomes during follow-up

                                  *Quartile 1*   *Quartile 2*   *Quartile 3*   *Quartile 4*   P*-value*
  ------------------------------ -------------- -------------- -------------- -------------- -----------
  All events, *n* (%)               1 (1.3)        3 (3.9)        8 (10.3)       7 (9.9)        0.028
  All-cause mortality, *n* (%)       0 (0)         2 (2.6)        3 (3.9)        1 (1.4)        0.333
  IHD, *n* (%)                       0 (0)         1 (1.3)        4 (5.3)        5 (5.6)        0.055
  Stroke, *n* (%)                   1 (1.3)         0 (0)         1 (1.3)        1 (1.4)        0.793

Abbreviation: IHD, ischemic heart disease.

###### Association between submaximal SBP (at stage 4 of the Naughton/Balke protocol) and clinical outcomes

                                                                                   *Unadjusted*                *Adjusted for age and sex*   *Model 1 adjusted for resting SBP and DBP*   *Model 2 adjusted for model 1 and Framingham score*   *Model 3 adjusted for model 2 and other variables*[a](#t6-fn1){ref-type="fn"}
  ------------------------------------------------------- ------------------------ --------------------------- ---------------------------- -------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------
  Stage 4 SBP (per quartile increment)                    HR (95% CI), *P*-value   1.76 (1.12--2.78), 0.010    1.60 (1.01---2.54), 0.044    1.99 (1.23--3.23), 0.005                     1.82 (1.13--2.95), 0.014                              1.74 (1.04--2.89), 0.035
  Stage 4 SBP quartile 3 (*vs*. quartile 1 and 2)         HR (95% CI), *P*-value   3.92 (1.18--13.01), 0.026   3.06 (0.92--10.16), 0.068    4.52 (1.33--15.29), 0.015                    3.82 (1.14--12.84), 0.030                             4.69 (1.28--17.13), 0.020
  Stage 4 SBP quartile 4 (*vs*. quartile 1 and 2)         HR (95% CI), *P*-value   3.90 (1.14--13.33), 0.030   2.94 (0.83--10.34), 0.094    5.16 (1.42--18.80), 0.013                    4.08 (1.12--14.87), 0.033                             3.65 (0.92--14.50), 0.065
  Stage 4 SBP upper 50% (\>180 mm Hg) (*vs*. lower 50%)   HR (95% CI), *P*-value   3.74 (1.24--11.28), 0.019   2.89 (0.95--8.6), 0.062      4.52 (1.44--14.13), 0.010                    3.78 (1.22--11.73), 0.022                             4.00 (1.19--13.44), 0.025

Abbreviations: CI, confidence interval; HR, heart rate; SBP, systolic blood pressure.

Other variables included body mass index, exercise capacity, daytime SBP and night SBP.
